Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05134337 · ClinicalTrials.gov registry record · Phase 1
Study of the Effects of Itraconazole and Rifampin on LOXO-305 in Healthy Participants
A Phase 1 study, sponsored by Loxo Oncology.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT05134337 is a Phase 1 study that has completed, run by Loxo Oncology. The registered enrollment target is 27 participants.
The verdict
NCT05134337, a Phase 1 study, has completed, sponsored by Loxo Oncology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
The main purpose of this study is to learn about how itraconazole and rifampin affect LOXO-305 in healthy participants. Participation could last about 8 weeks.
Interventions
- DRUG Rifampin
- DRUG Itraconazole
- DRUG LOXO-305
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2020-02-12 |
| Est. Completion | 2020-10-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05134337
The ClinicalTrials.gov registry entry for NCT05134337 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Loxo Oncology, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Rifampin is the first listed.
NCT05134337 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05134337 about?
NCT05134337 is a clinical study titled "Study of the Effects of Itraconazole and Rifampin on LOXO-305 in Healthy Participants". The main purpose of this study is to learn about how itraconazole and rifampin affect LOXO-305 in healthy participants. Participation could last about 8 weeks.
What is the current status of trial NCT05134337?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2020-02-12. Estimated completion is 2020-10-30.
What interventions are being tested in trial NCT05134337?
The interventions under investigation include: Rifampin (DRUG), Itraconazole (DRUG), LOXO-305 (DRUG).
Who is sponsoring clinical trial NCT05134337?
This trial is sponsored by Loxo Oncology, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.